FindTrial
Sign In

A Registry Study of Luvomeitinib for the Treatment of Adult Langerhans Cell Histiocytosis (LCH) and Histiocytic Tumors in China

A Registry Study of Luvomeitinib for the Treatment of Adult Langerhans Cell Histiocytosis (LCH) and Histiocytic Tumors in China

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124397
Enrollment
Unknown
Registered
2026-05-12
Start date
2026-05-15
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Langerhans cell histiocytosis in adults

Interventions

Observation group:None

Sponsors

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age >=18 years, male or female. 2.Patients with histopathologically confirmed Langerhans cell histiocytosis (LCH) and other histiocytic neoplasms. 3.Patients currently using (including those who have used in the past) luwometinib. 4.Patients voluntarily participate in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients who withdraw informed consent.

Design outcomes

Primary

MeasureTime frame
Efficacy was assessed according to PRC criteria. Tumor assessments will be performed by means of PET-CT every 12 months (± 30 days) until disease progression, death, voluntary withdrawal of the patient from study treatment, or termination of the study;—

Countries

China

Contacts

Public ContactJian Li

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

lijian@pumch.cn+86 10 69155027

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026